PDCD1 and cancer: Compared to single‐agent anti‐PD1/PD‐L1 therapy, inducing non‐apoptotic forms of RCD, such as ferroptosis, pyroptosis, or necroptosis, may substantially overcome resistance to anti‐PD1/PD‐L1 therapy, rendering cancer cells more susceptible to immunotherapy.